Accenture Named to 2026 Fortune Best Workplaces for Women List
Accenture has been recognized on the 2026 Fortune Best Workplaces for Women list, based on employee survey data.
Stocks · News reference
Stock Market Today: S&P 500 Slips as Micron Fails to Impress, 10-Year Yields Ease to 5.25%
Micron slides despite a record quarter as the 10-year yield nears 5.3% and oil tops $92, while Accenture, Coherent and Vicor surge on earnings and AI optics.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
ACNALNYAMZNAPPCOHRCTSHDIAFICOFRMIGLDIBITIGVIWMKIELITEMUNKEOIHPHOQQQSNPSTEMVICRVOOVSNTXLBXLCXLEXLFXLIXLKXLREXLUXLVXOP
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Accenture Insider Purchases Shares Worth Over $3 Million
An Accenture insider has acquired shares of the company valued at approximately $3 million, as disclosed in a recent SEC filing.
Accenture Named a Leader in 2026 ISG Provider Lens AWS Ecosystem Partners Report for the U.K.
Accenture has been recognized as a leader across all four quadrants in the 2026 ISG Provider Lens AWS Ecosystem Partners report for the United Kingdom.
Accenture Federal Services Named Strategic Go-to-Market Partner for Dragos Public Sector
Accenture Federal Services has been selected as a strategic go-to-market partner by Dragos Public Sector to help federal agencies secure operational technology.
Alnylam Announces Positive Initial Phase 1b Data for Brezosiran in Huntington's Disease
Alnylam Pharmaceuticals reported positive initial Phase 1b clinical trial results for brezosiran (ALN-HTT02), demonstrating deep and durable reductions of mutant huntingtin protein in patients with Huntington's disease.
Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight
Over 200 companies are advancing more than 240 pipeline Alzheimer's disease therapies across various clinical development stages. The market is being driven by an aging population, rising disease prevalence, and the emergence of disease-modifying therapies that enable earlier intervention and biomarker-guided care. Two therapies have recently received FDA approval: KISUNLA (donanemab) from Eli Lilly and LEQEMBI (lecanemab-irmb) from Eisai/Biogen, both targeting amyloid plaques to slow disease progression.